Date Filed | Type | Description |
03/30/2021 |
GN
| Fennec Announces Fiscal Year 2020 Financial Results and Provides Business Update |
02/11/2021 |
GN
| SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Forest Road Acquisition Corp. Merger |
11/16/2020 |
GN
| Fennec Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update |
09/21/2020 |
GN
| Fennec Announces Issuance of U.S. Patent for PEDMARK™ |
08/12/2020 |
GN
| Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences |
08/11/2020 |
GN
| Fennec Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors |
08/05/2020 |
GN
| Fennec Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business Update |
06/26/2020 |
GN
| Fennec Pharmaceuticals Announces Amendment to Increase Existing Senior Debt Facility |
06/22/2020 |
GN
| Fennec Announces Results of Annual Meeting |
05/14/2020 |
GN
| Fennec Pharmaceuticals Announces First Quarter 2020 Financial Results and Provides Business Update |
05/08/2020 |
GN
| Fennec Announces Exercise and Closing of Underwriters' Option to Purchase Additional Shares |
04/29/2020 |
GN
| Fennec Announces Proposed Public Offering of Common Shares |
04/13/2020 |
GN
| Fennec Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of New Drug Application for PEDMARK™ |
03/05/2020 |
GN
| Fennec Announces Issuance of U.S. Patent for Use of PEDMARK™ |
02/28/2020 |
GN
| Fennec Pharmaceuticals Receives European Medicines Agency Validation for Marketing Authorization Application for Sodium Thiosulfate |
11/12/2019 |
GN
| Fennec Provides Business Update and Announces Third Quarter 2019 Financial Results |
10/02/2019 |
GN
| Fennec to Present at the 2019 Cantor Global Healthcare Conference on October 4, 2019 |
09/24/2019 |
GN
| Fennec Appoints Jodi A. Cook, PhD to Its Board of Directors |
09/09/2019 |
GN
| Fennec Appoints Shubh Goel as Chief Commercial Officer |
06/19/2019 |
GN
| Fennec Announces Results of Annual Meeting |
02/04/2019 |
GN
| Fennec Pharmaceuticals Announces $12.5 Million Debt Financing With Bridge Bank |
12/20/2018 |
GN
| Fennec Pharmaceuticals Initiates Rolling New Drug Application to U.s. Food and Drug Administration for PEDMARK™ |
11/16/2018 |
GN
| Fennec Pharmaceuticals Announces Scientific Symposium on Ototoxicity in Pediatric Cancer Patients at the 50th Congress of the International Society of Pediatric Oncology (SIOP) 2018 Meeting |
11/13/2018 |
GN
| Fennec Provides Business Update and Announces Third Quarter 2018 Financial Results |
09/26/2018 |
GN
| Fennec to Present at Cantor Fitzgerald Global Healthcare Conference on October 1, 2018 in New York City |
08/13/2018 |
GN
| Fennec Provides Business Update and Announces Second Quarter 2018 Financial Results |
08/07/2018 |
GN
| Fennec Pharmaceuticals Receives Positive Opinion on the Pediatric Investigation Plan From European Medicines Agency for PEDMARK(TM) and Confirmation of Eligibility for a Pediatric Use Marketing Authorization |
06/21/2018 |
GN
| Fennec Announces Publication of Pedmark(TM) Siopel 6 Clinical Data in the New England Journal of Medicine |
06/11/2018 |
GN
| Fennec Pharmaceuticals Set to Join Russell 3000 Index |
06/08/2018 |
GN
| Fennec Announces Results of Annual Meeting |
05/14/2018 |
GN
| Fennec Provides Business Update and Announces First Quarter 2018 Financial Results |
03/27/2018 |
GN
| Fennec Pharmaceuticals Receives Breakthrough Therapy Designation by FDA for PEDMARK™ |
03/26/2018 |
GN
| Fennec Provides Business Update and Announces Fiscal Year Ended December 31, 2017 Financial Results |
03/21/2018 |
GN
| Fennec Pharmaceuticals Receives Fast Track Designation by FDA for PEDMARK |
|